Moneycontrol Be a Pro
Get App
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Dec 05, 16:00
2870.15
-8.55 (-0.3%)
VOLUME 11,422
LIVE
NSE
Dec 05, 15:59
2871.60
-6.25 (-0.22%)
VOLUME 433,761
News on Dr Reddys Laboratories
Select Year: 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Dr Reddy's Laboratories can touch Rs 840-880

1.10 pm | 28 Dec 2006

Ambareesh Baliga of Karvy Stock Broking is of the view that Dr Reddy's Laboratories can touch Rs 840-880....

Above Rs 820, Dr Reddy's Lab has target of Rs 910

12.53 pm | 28 Dec 2006

Technical Analyst, Ashwani Gujral is of the view that above Rs 820, Dr Reddy's Laboratories has target of Rs 910....

Dr Reddys Labs market performer; target of Rs 840: Karvy

11.36 am | 28 Dec 2006

Broking house, Karvy Stock Broking is bullish on Dr Reddys Laboratories and believes that it would be a market performer with a target price of Rs 84...

Hold Dr Reddy's Labs; target of Rs 900: Angel Broking

11.16 am | 28 Dec 2006

Broking house, Angel Broking has maintained hold rating on the Dr Reddys Laboratories with a target price of Rs 900....

Dr Reddy's gets USFDA nod for Ondansetron

8.28 am | 28 Dec 2006

Dr Reddy's Laboratories Ltd today got the final approval for Ondansetron Hydrochloride, the generic equivalent of the blockbuster drug `Zofran', from ...

Stay invested in Dr Reddy's 

6.53 pm | 27 Dec 2006

Rajen Shah of Angel Broking is of the view that Dr Reddy's reasonably priced at current levels so investors should hold on to it....

Sukhani not very upbeat on Dr Reddy's Lab 

5.48 pm | 27 Dec 2006

Technical Analyst, Sudarshan Sukhani not very upbeat in the short-term in Dr Reddys Laboratories....

Zofran to help build US business: Dr Reddy's 

3.10 pm | 27 Dec 2006

VC & CEO of Dr Reddy's Laboratories, GV Prasad comments on getting the exclusivity for Ondansetron soon after the rights for Simvastatin and Proscar g...

Dr Reddys announces final approval of Ondansetron tablets

1.25 pm | 27 Dec 2006

Dr Reddys announces final approval of Ondansetron tablets with 180-days of marketing exclusivity...

Perlecan Pharma moves Dr Reddys drug to clinical trial

6.13 pm | 26 Dec 2006

Perlecan Pharma moves Dr Reddys novel anti-diabetic drug candidate to Phase I clinical trial...

World's first polypill trial

5.15 pm | 13 Dec 2006

World's first polypill trial...

ACC, Grasim looks good 

5.02 pm | 13 Dec 2006

Technical Analyst, Prakash Gaba is of the view that Associated Cement Companies, ACC, Grasim Industries looks good in cement pack....

Dr Reddy crosses USD 1 billion in revenues

6.18 pm | 12 Dec 2006

Dr Reddy has crossed a billion dollars in revenues, and that makes it the second Indian company after Ranbaxy to scale the magic figure, reports CNBC-...

Ranbaxy can touch Rs 350

3.45 pm | 12 Dec 2006

Shishir Kedia of Anand Rathi Securities is of the view that Ranbaxy can touch Rs 350 levels....

Buy Dr Reddy's Laboratories: DSP Merrill Lynch

3.46 pm | 11 Dec 2006

Broking house, DSP Merrill Lynch is bullish on Dr Reddy's Laboratories and has maintained buy rating on the stock....

Dr Reddy's eyes European markets 

10.54 am | 08 Dec 2006

Dr Reddy's is looking at acquisition in European markets. CEO Satish Reddy added the company is also gearing up for the launch of their new poly pill,...

Dr Reddy's teams up with Auckland varsity

8.15 am | 08 Dec 2006

Researchers at the University of Auckland have teamed up with Dr Reddy's Laboratories, Hyderabad to undertake trials of a new Polypill that could prov...

Cipla can add another Rs 80-85

12.13 pm | 06 Dec 2006

Ambareesh Baliga of Karvy Stock Broking feels that Cipla can add another Rs 80-85 in 12-15 month time frame....

Biotech versions: the next big thing?

8.10 pm | 04 Dec 2006

In Europe they are called biosimilars and the us FDA calls them follow on protein products but copies of biotech drugs could be the next big opportuni...

Buy Dr Reddy's Labs with a target of Rs 800: Motilal Oswal

2.57 pm | 01 Dec 2006

Broking house, Motilal Oswal has recommended buy rating Dr Reddy's Laboratories with a target of Rs 800....

1 2 3 4 5 6 7 8 9 10Next »
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.